Why in news?

A new study by the Indian Council of Medical Research (ICMR) has found that infections caused by antibiotic-resistant Gram-negative bacteria are deadlier and costlier to treat than infections caused by drug-susceptible strains.

India's antimicrobial resistance (AMR) crisis goes well beyond antibiotic overuse. Delayed diagnosis, hospital transmission and weak infection control are equally responsible.

What’s in Today’s Article?

• Understanding Gram-Negative Bacteria and Carbapenems
• Key Findings of the ICMR Study
• The Hidden Economic Burden
• A Signal, Not a Verdict, on Newer Drugs
• Antibiotics Cannot Replace Infection Prevention

Understanding Gram-Negative Bacteria and Carbapenems

• Gram-negative bacteria have a thin peptidoglycan cell wall and an outer membrane containing lipopolysaccharides. They stain pink or red during Gram staining.
• They cause infections in the lungs, urinary tract, wounds and bloodstream. Common hospital pathogens in this group include Escherichia coli (E. coli), Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa.
• Carbapenems are a powerful class of antibiotics used for serious infections. They are often the last line of defence.
• When bacteria become resistant to carbapenems, doctors are left with very few effective medicines.

Key Findings of the ICMR Study

• The study was conducted by ICMR's antimicrobial resistance surveillance network across 20 tertiary-care hospitals between April 2022 and April 2025.
• Mortality was consistently higher among patients with carbapenem-resistant infections across all four major pathogens. The relative risk of death was 1.16 to 1.43 times higher.
• More than 61 per cent of Gram-negative infections in the study were carbapenem-resistant.
• Experts call carbapenem resistance a major threat to patient survival, especially in severe and bloodstream infections. However, they caution against treating resistance as an entirely independent cause of death.
• Severity of illness, timing of treatment, source control and patient factors also shape outcomes. Resistance is best understood as an important marker of excess mortality.
• The study also points to healthcare-associated transmission, invasive devices, recent surgery, antibiotic pressure and gaps in infection prevention and diagnosis.
• AMR is the product of a complex interaction among these factors. It cannot be reduced to antibiotic overuse alone.

The Hidden Economic Burden

• The study's cost figures are conservative. Researchers looked only at the cost of antibiotics available under the Jan Aushadhi scheme.
• They excluded ICU charges, bed costs, diagnostics, procedures, supportive care and consultation fees.
• Even on this narrow measure, antibiotic costs for resistant infections were 1.1 to 2 times higher. The true burden on patients, families and the healthcare system is likely far greater.

A Signal, Not a Verdict, on Newer Drugs

• The antibiotic Ceftazidime-avibactam was linked to better outcomes in some resistant E. coli and K. pneumoniae infections, including bloodstream infections. Experts describe this as an important signal rather than proof of superiority.
• The study was observational and could not fully adjust for disease severity, timing of therapy or resistance mechanisms.
• The results reflect real-world treatment patterns in India, not a definitive drug ranking.
• This underlines the need for better diagnostics to guide treatment instead of simply escalating to newer, broader antibiotics.

Antibiotics Cannot Replace Infection Prevention

• More than 85 per cent of bloodstream infections in the study were healthcare-associated. This shows that Indian hospitals are relying on antibiotics to fix what is essentially an infection-prevention failure.
• Hospitals must place infection prevention and control at the centre of their AMR response.
• This includes hand hygiene, prevention of device-associated infections, appropriate insertion and early removal of invasive devices, environmental cleaning, surgical infection prevention and surveillance of healthcare-associated infections.
• Antimicrobial stewardship is equally vital. The answer to rising resistance is not stronger antibiotics.
• It is to prevent infections, diagnose them quickly and use the narrowest effective antibiotic for the shortest appropriate duration.

The Way Forward: An Integrated Response

• First, India must move from isolate-based surveillance to integrated surveillance that links laboratory results with patient outcomes, mortality and treatment.
• Second, faster and more accurate diagnostics are needed to distinguish bacterial from non-bacterial illness and detect resistance early.
• Third, antimicrobial stewardship must become routine clinical practice, not an optional programme.
• Fourth, infection prevention must receive as much attention as prescribing.
• Finally, India needs responsible access to newer antimicrobials, backed by stewardship, so these drugs remain effective when truly needed.

Conclusion

The ICMR study confirms that carbapenem resistance is a serious threat to survival and a heavy economic burden. India's AMR crisis cannot be solved by discovering a new antibiotic each time an old one fails.

Preventing infections, diagnosing them early and preserving existing antibiotics must become the core of national health policy.